Tuesday, October 10, 2017


CATB Catabasis Pharmaceuticals, Inc. gains 25% Oct 10, 2017

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat inflammatory and metabolic diseases. Its product pipeline includes CAT-1004, an oral small molecule that has completed Phase 1 clinical trials for the treatment of duchenne muscular dystrophy; CAT-2054, which is in Phase I clinical trial for the treatment of hypercholesterolemia in patients for whom existing treatments are insufficient; and CAT-2003 that has completed Phase IIa trials to the treatment of patients with elevated triglycerides or hypertriglyceridemia. It is also developing CAT-4001 that is in preclinical stage for the treatment for severe, rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis. The company has a collaboration with dystrophy association for the development of CAT-1004, a treatment for duchenne muscular dystrophy. Catabasis Pharmaceuticals, Inc. was founded in 2008 and is Cambridge, Massachusetts.

Subscribe by Email

Follow Updates Articles from This Blog via Email

No Comments

TradeVisor Product Review

Review I II III IV

Blog Archive